Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

News Conference News TCT 2020

Global EXPAND: Next-Gen MitraClip Cuts MR, Boosts QoL at 1 Year

L.A. McKeown

October 16, 2020

Presentation TCT 2019

Case 2 (B): Percutaneous Closure of a Blalock-Taussig Shunt, a Systemic-Pulmonary Collateral, and Closure of a Cavo-Atrial Fenestration in a Single Procedure

Presenter: Jesus Omar Hernandez Marquez

September 27, 2019

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

Presentation TCT 2018

ORBITA One Year Later: What Would I Do Differently, If Anything?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2017

Technical Opportunities Part 2: Telehealth, Cloud-Based Systems, and Centers of Excellence

Presenter: G. Burkhard Mackensen, Robert J. Siegel, João L Cavalcante

November 01, 2017

Presentation TCT 2012

Pragmatic Pre- and Post-Market Global Harmonization: Lessons from Japan and the United States

Presenter: Kenneth Cavanaugh Jr

October 24, 2012

Presentation TCT 2012

CLI and Device Intervention Across the Pacific: An FDA View

Presenter: Kenneth Cavanaugh Jr

October 24, 2012

Advertisement

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Global EXPAND: Next-Gen MitraClip Cuts MR, Boosts QoL at 1 Year

Case 2 (B): Percutaneous Closure of a Blalock-Taussig Shunt, a Systemic-Pulmonary Collateral, and Closure of a Cavo-Atrial Fenestration in a Single Procedure

Patient Perspectives on Sham-Controlled Trials

FDA Perspectives on Sham-Controlled Trials

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

ORBITA One Year Later: What Would I Do Differently, If Anything?

Technical Opportunities Part 2: Telehealth, Cloud-Based Systems, and Centers of Excellence

Pragmatic Pre- and Post-Market Global Harmonization: Lessons from Japan and the United States

CLI and Device Intervention Across the Pacific: An FDA View

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content